267 related articles for article (PubMed ID: 30367282)
21. Cardiovascular disease in survivors of childhood cancer.
Bansal N; Amdani SM; Hutchins KK; Lipshultz SE
Curr Opin Pediatr; 2018 Oct; 30(5):628-638. PubMed ID: 30124579
[TBL] [Abstract][Full Text] [Related]
22. Cardio-oncology, the myth of Sisyphus, and cardiovascular disease in breast cancer survivors.
Mavrogeni SI; Sfendouraki E; Markousis-Mavrogenis G; Rigopoulos A; Noutsias M; Kolovou G; Angeli C; Tousoulis D
Heart Fail Rev; 2019 Nov; 24(6):977-987. PubMed ID: 31134427
[TBL] [Abstract][Full Text] [Related]
23. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease.
Drafts BC; Twomley KM; D'Agostino R; Lawrence J; Avis N; Ellis LR; Thohan V; Jordan J; Melin SA; Torti FM; Little WC; Hamilton CA; Hundley WG
JACC Cardiovasc Imaging; 2013 Aug; 6(8):877-85. PubMed ID: 23643285
[TBL] [Abstract][Full Text] [Related]
24. The Role of Cardiovascular Magnetic Resonance in the Management of Patients with Cancer.
Gregory Hundley W
Curr Treat Options Cardiovasc Med; 2018 Mar; 20(4):30. PubMed ID: 29556816
[TBL] [Abstract][Full Text] [Related]
25. Role of cardiovascular magnetic resonance in early detection and treatment of cardiac dysfunction in oncology patients.
Vallabhaneni S; Zhang KW; Alvarez-Cardona JA; Mitchell JD; Steen H; Woodard PK; Lenihan DJ
Int J Cardiovasc Imaging; 2021 Oct; 37(10):3003-3017. PubMed ID: 33982196
[TBL] [Abstract][Full Text] [Related]
26. Cardiovascular Magnetic Resonance in the Oncology Patient.
Jordan JH; Todd RM; Vasu S; Hundley WG
JACC Cardiovasc Imaging; 2018 Aug; 11(8):1150-1172. PubMed ID: 30092971
[TBL] [Abstract][Full Text] [Related]
27. The role of cardiac magnetic resonance imaging in the detection and monitoring of cardiotoxicity in patients with breast cancer after treatment: a comprehensive review.
Jafari F; Safaei AM; Hosseini L; Asadian S; Kamangar TM; Zadehbagheri F; Rezaeian N
Heart Fail Rev; 2021 May; 26(3):679-697. PubMed ID: 33029698
[TBL] [Abstract][Full Text] [Related]
28. The Role of Imaging with Cardiac Computed Tomography in Cardio-Oncology Patients.
Pitekova B; Ravi S; Shah SV; Mladosievicova B; Heitner S; Ferencik M
Curr Cardiol Rep; 2016 Sep; 18(9):87. PubMed ID: 27443383
[TBL] [Abstract][Full Text] [Related]
29. Clinical and Research Tools for the Study of Cardiovascular Effects of Cancer Therapy.
Feroze RA; Leya J; Herron T; Hayek SS
J Cardiovasc Transl Res; 2020 Jun; 13(3):417-430. PubMed ID: 32472498
[TBL] [Abstract][Full Text] [Related]
30. Feasibility of Echocardiographic Techniques to Detect Subclinical Cancer Therapeutics-Related Cardiac Dysfunction among High-Dose Patients When Compared with Cardiac Magnetic Resonance Imaging.
Toro-Salazar OH; Ferranti J; Lorenzoni R; Walling S; Mazur W; Raman SV; Davey BT; Gillan E; O'Loughlin M; Klas B; Hor KN
J Am Soc Echocardiogr; 2016 Feb; 29(2):119-31. PubMed ID: 26678319
[TBL] [Abstract][Full Text] [Related]
31. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC).
Čelutkienė J; Pudil R; López-Fernández T; Grapsa J; Nihoyannopoulos P; Bergler-Klein J; Cohen-Solal A; Farmakis D; Tocchetti CG; von Haehling S; Barberis V; Flachskampf FA; Čeponienė I; Haegler-Laube E; Suter T; Lapinskas T; Prasad S; de Boer RA; Wechalekar K; Anker MS; Iakobishvili Z; Bucciarelli-Ducci C; Schulz-Menger J; Cosyns B; Gaemperli O; Belenkov Y; Hulot JS; Galderisi M; Lancellotti P; Bax J; Marwick TH; Chioncel O; Jaarsma T; Mullens W; Piepoli M; Thum T; Heymans S; Mueller C; Moura B; Ruschitzka F; Zamorano JL; Rosano G; Coats AJS; Asteggiano R; Seferovic P; Edvardsen T; Lyon AR
Eur J Heart Fail; 2020 Sep; 22(9):1504-1524. PubMed ID: 32621569
[TBL] [Abstract][Full Text] [Related]
32. Cardiac MRI for the evaluation of oncologic cardiotoxicity.
Löffler AI; Salerno M
J Nucl Cardiol; 2018 Dec; 25(6):2148-2158. PubMed ID: 29736616
[TBL] [Abstract][Full Text] [Related]
33. Strategies to Prevent Cardiotoxicity.
Graffagnino J; Kondapalli L; Arora G; Hawi R; Lenneman CG
Curr Treat Options Oncol; 2020 Apr; 21(4):32. PubMed ID: 32270293
[TBL] [Abstract][Full Text] [Related]
34. Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonance.
Jordan JH; D'Agostino RB; Hamilton CA; Vasu S; Hall ME; Kitzman DW; Thohan V; Lawrence JA; Ellis LR; Lash TL; Hundley WG
Circ Cardiovasc Imaging; 2014 Nov; 7(6):872-9. PubMed ID: 25273568
[TBL] [Abstract][Full Text] [Related]
35. Anthracycline-Associated T1 Mapping Characteristics Are Elevated Independent of the Presence of Cardiovascular Comorbidities in Cancer Survivors.
Jordan JH; Vasu S; Morgan TM; D'Agostino RB; Meléndez GC; Hamilton CA; Arai AE; Liu S; Liu CY; Lima JA; Bluemke DA; Burke GL; Hundley WG
Circ Cardiovasc Imaging; 2016 Aug; 9(8):. PubMed ID: 27502058
[TBL] [Abstract][Full Text] [Related]
36. Echocardiographic Assessment of Cardiotoxic Effects of Cancer Therapy.
Bottinor WJ; Migliore CK; Lenneman CA; Stoddard MF
Curr Cardiol Rep; 2016 Oct; 18(10):99. PubMed ID: 27566332
[TBL] [Abstract][Full Text] [Related]
37. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease.
Totzeck M; Schuler M; Stuschke M; Heusch G; Rassaf T
Int J Cardiol; 2019 Apr; 280():163-175. PubMed ID: 30661849
[TBL] [Abstract][Full Text] [Related]
38. Cardiovascular safety of oncologic agents: A double-edged sword even in the era of targeted therapies - part 1.
Manolis AA; Manolis TA; Mikhailidis DP; Manolis AS
Expert Opin Drug Saf; 2018 Sep; 17(9):875-892. PubMed ID: 30126304
[TBL] [Abstract][Full Text] [Related]
39. Molecular basis of cancer-therapy-induced cardiotoxicity: introducing microRNA biomarkers for early assessment of subclinical myocardial injury.
Sandhu H; Maddock H
Clin Sci (Lond); 2014 Mar; 126(6):377-400. PubMed ID: 24274966
[TBL] [Abstract][Full Text] [Related]
40. Out of the frying pan and into the fire: damage-associated molecular patterns and cardiovascular toxicity following cancer therapy.
Klee NS; McCarthy CG; Martinez-Quinones P; Webb RC
Ther Adv Cardiovasc Dis; 2017 Nov; 11(11):297-317. PubMed ID: 28911261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
